Clinical trials: Prostate Disease
Cancer
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
The primary purpose of this study is to determine the maximally tolerated dose (MTD) of HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus carboplatin, cisplatin plus etoposide, or…
- Trial name
- NCT01604863
- Testing
- HGS1036 + Paclitaxel + Carboplatin, HGS1036 + Cisplatin + Etoposide, HGS1036 + Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Prostate Cancer, Prostatic Neoplasms
Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448
The phase 1 portion of this study is an open-label, multicenter, dose-escalation study of 1-month depot TAK-448 in adult males with prostate cancer who are either on gonadotropin releasing hormone (GnRH) therapy or who might be…
- Trial name
- NCT01132404
- Testing
- Leuprorelin, TAK-448
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Over-Active Bladder
VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate
The purpose of this study is to determine if Vesicare (Solifenacin succinate) is effective in treating over-active bladder symptoms during radiation therapy of the prostate.
- Trial name
- NCT01777217
- Testing
- Solifenacin succinate
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Advanced Research Network
Benign Prostatic Hyperplasia, Enlarged Prostate
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
The purpose of this study is to evaluate the efficacy of lonidamine (50mg, 150mg) compared to placebo in subjects with symptomatic BPH.
- Trial name
- NCT00435448
- Testing
- Lonidamine
- Where
- 58 sites in Germany, Hungary and 2 more
- Volunteers
- 480 people
- Sponsor
- Threshold Pharmaceuticals
Prostatic Neoplasms, Prostate Cancer
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
The purpose of this study was to evaluate the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of PSMA positive tumors using histopathology as Standard of Truth (SoT).
- Trial name
- GuideView (NCT04838626)
- Testing
- [18F]CTT1057
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 195 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients
The purpose of the study, is to determine the percentage of patients for whom the initial LHRH prescription has been renewed
- Trial name
- ANAREN (NCT03017313)
- Testing
- LHRH analogues
- Where
- 27 sites in Spain
- Volunteers
- 510 people
- Sponsor
- Ipsen
Breast Cancer, Head and Neck Squamous Cell Carcinoma
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
This study is to evaluate diagnostic performance, safety and timing of post-dose imaging of ONM-100, an intraoperative fluorescence imaging agent for the detection of cancer in patients with solid tumors undergoing routine…
- Conditions
- Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT03735680
- Testing
- ONM-100
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- OncoNano Medicine, Inc.
Prostate Cancer, Castration-resistant Prostate Cancer
A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
The aim of this trial is to evaluate SHR3680 combined with SHR3162 and SHR3680 single drug to improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's overall survival (OS) is superior to placebo.
- Trial name
- NCT04102124
- Testing
- SHR3680, SHR3162
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer
A Phase I/II study of an in-situ therapeutic cancer vaccine. Vaccines contain a source of antigen and and adjuvant. In this study the source of tumor antigen comes from the killing of a selected tumor by cryoablation (killing…
- Conditions
- Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT01065441
- Testing
- AlloStim, Cryoablation
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Michael Har-Noy
Breast Cancer, Prostate Cancer
A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors
This is a Phase 1-1b multicenter clinical study to evaluate the safety, efficacy, and dosimetry of [177Lu]Lu-A9-0631 and [225Ac]Ac-0642 in participants with Gastrin-Releasing Peptide Receptor (GRPR) expressing locally advanced…
- Conditions
- Breast Cancer, Prostate Cancer, Colorectal Cancer, GRPR-positive Solid Tumors
- Trial name
- NCT07661641
- Testing
- [68Ga]Ga-A9-6217, Low dose [177Lu]Lu-A9-0631, [177Lu]Lu-A9-0631
- Where
- 2 sites in Australia
- Volunteers
- 115 people
- Sponsor
- Alpha-9 Oncology USA Inc.
Advanced Metastatic Castration Resistant Prostate Cancer
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.
- Trial name
- NCT06609005
- Testing
- INV-9956
- Where
- 22 sites in United States, China
- Volunteers
- 84 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Solid Malignancies, Non-Hodgkin's Lymphoma
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
The purposes of this study are to determine: the largest dose of AQ4N that can be safely given once a week for three weeks out of a 4 week cycle the side effects of AQ4N when given on the above schedule how much AQ4N is in the…
- Trial name
- NCT00090727
- Testing
- AQ4N
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novacea
Prostatic Neoplasms, Adenocarcinoma
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose…
- Trial name
- NCT04644770
- Testing
- JNJ-69086420, JNJ-78278343, Stereotactic body radiation therapy
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
The purpose of this study is to determine if asymptomatic or minimally symptomatic patients with metastatic prostate cancer who have not received chemotherapy live longer when treated with ipilimumab than those treated with a…
- Trial name
- NCT01057810
- Testing
- Ipilimumab
- Where
- 134 sites in United States, Argentina and 22 more
- Volunteers
- 837 people
- Sponsor
- Bristol-Myers Squibb
Prostatic Neoplasms
Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer
This study involves the use of an experimental product, TG4010. The purpose of the study is to determine if TG4010 can stimulate the body's immune system to help it fight the cancer.
- Trial name
- NCT00040170
- Testing
- MVA-MUC1-IL2
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Transgene
Prostatic Neoplasms
EPO906 Therapy in Patients With Prostate Cancer
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause prostate cancer.
- Trial name
- NCT00035113
- Testing
- epothilone b
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed one or two…
- Trial name
- NCT00638690
- Testing
- Abiraterone acetate, Prednisone/prednisolone
- Where
- 127 sites in United States, Australia and 10 more
- Volunteers
- 1,195 people
- Sponsor
- Cougar Biotechnology, Inc.
Benign Prostatic Hyperplasia
Study to Compare the Safety and Pharmacokinetics of CKD-397
The purpose of this study is to compare the safety and pharmacokinetics profiles of CKD-397 in healthy male volunteers.
- Trial name
- CKD-397 (NCT02645890)
- Testing
- CKD-397, TD+TM
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Prostate Cancer, Benign Prostatic Hyperplasia
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
Emerging from a differential proteomic study of sample pairs of prostate cancer and benign tissue, annexin A3 (ANXA3) was chosen as a potential novel biomarker for the early and non-invasive diagnosis of prostate cancer.
- Conditions
- Prostate Cancer, Benign Prostatic Hyperplasia, Prostatic Intraepithelial Neoplasia
- Trial name
- NCT00400894
- Volunteers
- 750 people
- Sponsor
- ProteoSys AG
Benign Prostatic Hyperplasia
Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia
This is a multi-center, randomized, double-blinded, double-dummy, parallel group, 48-week study to evaluated the efficacy and safety of DKF-313 (dutasteride and tadalafil) in patients with benign prostatic hyperplasia.
- Trial name
- NCT04947631
- Testing
- DKF-313, Dutasteride, Tadalafil
- Where
- South Korea
- Volunteers
- 667 people
- Sponsor
- Dongkook Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.